Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 18/20 | 0.45 |
| ▸ | ADORA1 | P30542 | 3/20 | 0.40 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21814372 | 0.85 | ADORA2A (0.48) | ADORA2AADORA1HDAC1 | |
| SCHEMBL21583441 | 0.81 | ADORA2A (0.45) | ADORA2AADORA1HDAC1 | |
| SCHEMBL29502734 | 0.81 | ADORA2A (0.45) | ADORA2AADORA1HDAC1 | |
| SCHEMBL4045282 | 0.77 | ADORA2A (0.46) | ADORA2AADORA1 | |
| SCHEMBL23355745 | 0.73 | ADORA2A (0.53) | ADORA2AADORA1 | |
| SCHEMBL4048966 | 0.69 | ADORA2A (0.40) | ADORA2AADORA1 | |
| SCHEMBL23355623 | 0.69 | ADORA2A (0.60) | ADORA2AADORA1 | |
| SCHEMBL10564429 | 0.68 | ADORA2A (0.50) | ADORA2AADORA1 | |
| SCHEMBL930783 | 0.68 | KDM4E (0.49) | ADORA2AADORA1 | |
| SCHEMBL30738272 | 0.68 | ADORA2A (0.42) | ADORA2AADORA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210355104-A1 | ADENOSINE RECEPTOR BINDING COMPOUNDS | NIKANG THERAPEUTICS, INC. (US) | 2021-11-18 | — | — | US | disclosed |
| EP-3820474-A1 | ADENOSINE RECEPTOR BINDING COMPOUNDS | Nikang Therapeutics, Inc. (US) | 2021-05-19 | — | — | EP | disclosed |
| CN-112423758-A | Adenosine receptor binding compounds | 尼康治疗公司 | 2021-02-26 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210355104-A1 | ADENOSINE RECEPTOR BINDING COMPOUNDS | ADORA2A, ADORA1, ADORA3 | ADORA2A 1/4885ADORA1 2/4885HDAC1 2376/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.